市場調查報告書
商品編碼
1500547
轉染技術市場:按產品、方法、技術、應用和最終用戶分類 - 2024-2030 年全球預測Transfection Technologies Market by Product (Instrument, Reagent & Kits), Method (Cationic Lipid Transfection, Cotransfection, Electroporation), Technology, Applications, End-user - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年轉染技術市場規模為12.2億美元,預計2024年將達13.5億美元,2030年將達23.9億美元,複合年成長率為9.97%。
轉染技術將外源核酸引入細胞並產生基因改造細胞。它在分子生物學研究、基因治療和重組蛋白藥物開發中至關重要。轉染技術的不斷創新提供了更高的效率和更低的細胞毒性,正在推動市場成長。政府和私人組織增加研發資金,以及擴大基因組和基因編輯研究,也對市場環境產生正面影響。然而,先進轉染技術及相關產品的高成本限制了轉染技術解決方案的取得。對基因治療產品的嚴格監管要求可能會阻礙開發進度。此外,日益關注提高轉染效率和最小化細胞毒性效應可能是一個重要的潛在機會領域。開拓新型非病毒遞送系統和擴大商業性治療應用的製程也是市場成長的有希望的因素。
主要市場統計 | |
---|---|
基準年[2023] | 12.2億美元 |
預測年份 [2024] | 13.5億美元 |
預測年份 [2030] | 23.9億美元 |
複合年成長率(%) | 9.97% |
區域洞察
在美洲,美國和加拿大由於在生物技術和藥物研究方面的大量投資,在全球轉染技術市場中佔據重要地位。重要的生物技術公司的存在、強大的智慧財產權保護框架以及重大的研究舉措都強調了該地區對創新的承諾。最近關於非病毒基因轉移系統的專利反映了人們對提高轉染效率和安全性的持續關注。由於成員國之間的監管和資金籌措情況不同,歐盟 (EU) 的市場格局十分複雜。然而,歐盟範圍內促進基因組學和個人化醫療研究的努力正在推動對先進轉染解決方案的需求,特別是對將這些技術納入治療開發平臺。中東和非洲 (MEA) 是一個新興但快速成長的市場。對醫療保健基礎設施的投資和對生物醫學研究夥伴關係的更多關注是中東和非洲地區的主要趨勢。在中國、日本和印度等國家的推動下,亞太地區的轉染技術市場正在快速成長。對生物技術和醫療保健研究的大量投資、政府對基因組計劃的支持以及對個人化醫療日益成長的興趣正在推動亞太地區的成長。在基因治療和再生醫學研究的推動下,非病毒轉染方法的需求特別高。
FPNV定位矩陣
FPNV定位矩陣對於評估供應商在轉染技術市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢查了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對轉染技術市場中供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在轉染技術市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[193 Pages Report] The Transfection Technologies Market size was estimated at USD 1.22 billion in 2023 and expected to reach USD 1.35 billion in 2024, at a CAGR 9.97% to reach USD 2.39 billion by 2030.
Transfection technologies involve the introduction of foreign nucleic acids into cells to produce genetically modified cells. Transfection technologies are crucial in molecular biology research, gene therapy, and the development of recombinant protein drugs. Ongoing innovations in transfection techniques that offer higher efficiency and lower cytotoxicity are driving the market growth. Increased funding in R&D by governments and private entities and expansion in genomics and gene editing research is also positively influencing the market landscape. However, the high cost of advanced transfection technologies and related products limits the accessibility of transfection technology solutions. Stringent regulatory requirements for gene therapy products can impede development timelines. Moreover, Increased focus on enhancing transfection efficiency and minimizing the cytotoxic effects can serve as significant areas for potential opportunities. Developing novel, non-viral delivery systems and scaling up processes for commercial therapeutic applications are also promising for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.22 billion |
Estimated Year [2024] | USD 1.35 billion |
Forecast Year [2030] | USD 2.39 billion |
CAGR (%) | 9.97% |
Regional Insights
In the Americas, the United States and Canada hold a significant position in the global transfection technologies market, driven by substantial investments in biotechnology and pharmaceutical research. The presence of crucial biotech firms, a robust framework for intellectual property protection, and significant research initiatives underscore the commitment to innovation in the Americas region. Recent patents in non-viral gene delivery systems reflect the ongoing focus on improving transfection efficiency and safety. In the European Union, diverse regulatory and funding landscapes across member states create a complex market for transfection technologies. However, EU-wide initiatives to promote research in genomics and personalized medicine are driving demand for advanced transfection solutions, with particular interest in integrating these technologies into therapeutic development pipelines. The Middle East and Africa (MEA) present a nascent but rapidly growing market for transfection technologies. Investments in healthcare infrastructure and a growing focus on biomedical research partnerships are key trends in the MEA region. The Asia Pacific region, led by countries such as China, Japan, and India, is witnessing rapid growth in the transfection technologies market. Heavy investments in biotechnology and healthcare research, government support for genomics projects, and a growing emphasis on personalized medicine propel the growth in the APAC region. The demand for non-viral transfection methods is particularly high, driven by gene therapy and regenerative medicine research.
Market Insights
The market dynamics represent an ever-changing landscape of the Transfection Technologies Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Transfection Technologies Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Transfection Technologies Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Polyplus Launches FectoVIR-LV Transfection Reagent with New DOE Service Options
Polyplus, a subsidiary of Satorius, launched FectoVIR-LV, a groundbreaking transfection reagent specifically designed to enhance lentiviral vector (LV) production for gene-modified cell therapies including CAR-T and stem cell treatments. Recognizing the escalating demand for LVs as these therapies evolve, Polyplus offers a solution that addresses the critical need for scalability in production without compromising time or cost efficiency. FectoVIR-LV distinguishes itself by being animal component-free and optimized for scaling up in suspension HEK-293 cell systems, significantly improving LV yield and stability. [Published On: 2023-08-29]
BioCentriq and Kytopen Expand Partnership to Expedite Impact of Transformative Gene-Editing Technology on Cell Therapy Manufacturing
BioCentriq,has significantly enhanced its partnership with Kytopen, a cutting-edge startup emanating from MIT, aimed at revolutionizing transfection technologies. This partnership, has successively moved beyond its preliminary phase, wherein the combined efforts of BioCentriq and Kytopen meticulously evaluated the use of Kytopen's state-of-the-art Flowfect technology for T-cell transfection. [Published On: 2023-06-06]
Avectas Launches the Solupore Platform for the Clinical Manufacturing of Next- Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality
Avectas launched its pioneering Solupore platform during Advanced Therapies Week at the Miami Beach Convention Centre. Engineered to revolutionize cell therapy manufacturing, the Solupore system stands out for its non-viral, membrane-permeabilizing methodology, ensuring the delivery of various molecular cargoes-including mRNA, plasmids, RNP, and CRISPR/Cas9-while maintaining optimal cell health and functionality. This advancement opens new avenues for complex genetic editing and the delivery of challenging materials. [Published On: 2023-01-16]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Transfection Technologies Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Transfection Technologies Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Akron Biotech, Altogen Biosystems, Bio-Rad Laboratories, Inc., Biomol GmbH, Epoch Life Science, F. Hoffmann-La Roche AG, FUJIFILM Wako Pure Chemical Corporation, Geno Technology, Inc., Lonza Group, Maxcyte Inc., Merck KGaA, Mirus Bio, OriGene Technologies, Inc., OZ Biosciences SAS, Polyplus-transfection SA by Sartorius AG, Polysciences, Inc., Promega Corporation, Qiagen NV, Reprocell Inc., SignaGen Laboratories, Takara Bio Inc., Thermo Fisher Scientific, Inc., and VWR International, LLC by Avantor.
Market Segmentation & Coverage